Opportunities and challenges in developing tissue-agnostic anti-cancer drugs

Abstract

The rapid advances in the understanding of oncogenic process and the maturation of affordable precision diagnostic tools have enabled the development of targeted therapeutic agents, such as those targeting BCR-ABL, epithelial growth factor receptor L858R, EML4-anaplastic lymphoma kinase, and BRAF V600E, to treat cancers that harbor specific molecular alterations. Traditionally, each targeted drug has been developed for a particular tumor type where such alteration is most frequently found. Recently, the widespread adoption of next generation sequencing has led to an increase in the identification of rare and ultra-rare alterations, and, in some cases, the same rare alterations are found across multiple tumor types. The rarity of these alterations makes clinical trials traditionally designed for specific tumor types infeasible. As a result, tissue-agnostic trials have been developed to study the efficacy of these treatments and increase patient access. This review summarizes current successful cases of tissue-agnostic development, such as drugs targeting tropomyosin receptor kinase fusions, and proposes the next wave of potential tissue-agnostic targets, including fusions of ROS1, anaplastic lymphoma kinase, fibroblast growth factor receptor, and rearranged during transfection. In addition, the advantages and the challenges of such approach are discussed in the context of clinical development and approval.

Keywords

Tissue agnostic / basket trial / tropomyosin receptor kinase / anaplastic lymphoma kinase / ROS1 / fibroblast growth factor receptor / rearranged during transfection

References

[1] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[2] Garraway LA.Lessons from the cancer genome..Cell2013;153:17-37

[3] Bennett CW,Kim YJ.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer..Oncotarget2016;7:71013-35 PMCID:PMC5342606

[4] Luthra R,Roy-Chowdhuri S.Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges..Cancers (Basel)2015;7:2023-36 PMCID:PMC4695874

[5] Armenia J,Liu D,Kundra R.The long tail of oncogenic drivers in prostate cancer..Nat Genet2018;50:645-51 PMCID:PMC6107367

[6] Ding L,Wheeler DA,McLellan MD.Somatic mutations affect key pathways in lung adenocarcinoma..Nature2008;455:1069-75 PMCID:PMC2694412

[7] Stransky N,Tward AD,Cibulskis K.The mutational landscape of head and neck squamous cell carcinoma..Science2011;333:1157-60 PMCID:PMC3415217

[8] Santarpia L,Kelly CM,Szekely B.Deciphering and targeting oncogenic mutations and pathways in breast cancer..Oncologist2016;21:1063-78 PMCID:PMC5016060

[9] Hoadley KA,Wolf DM,Tamborero D.Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin..Cell2014;158:929-44 PMCID:PMC4152462

[10] Bailey MH,Porta-Pardo E,Bertrand D.Comprehensive characterization of cancer driver genes and mutations..Cell2018;174:1034-5

[11] Cohen MH,Johnson JR,Gobburu J.Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia..Clin Cancer Res2002;8:935-42

[12] Kazandjian D,Chen HY,Patel M.FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements..Oncologist2014;19:e5-11 PMCID:PMC4201002

[13] Rodriguez-Canales J,Wistuba II.Diagnosis and molecular classification of lung cancer..Cancer Treat Res2016;170:25-46

[14] Vuong D,Green B,Lakhani SR.Molecular classification of breast cancer..Virchows Arch2014;465:1-14

[15] Heestand GM.Molecular landscape of pancreatic cancer: implications for current clinical trials..Oncotarget2015;6:4553-61 PMCID:PMC4467098

[16] Offin M,Drilon A.Tumor-agnostic drug development..Am Soc Clin Oncol Educ Book2018;38:184-7

[17] Marcus L,Keegan P.FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors..Clin Cancer Res2019;25:3753-8

[18] Kummar S.TRK Inhibition: a new tumor-agnostic treatment strategy..Target Oncol2018;13:545-56

[19] Scott LJ.Larotrectinib: first global approval..Drugs2019;79:201-6

[20] Al-Salama ZT.Entrectinib: first global approval..Drugs2019;79:1477-83

[21] Doebele RC,Paz-Ares L,Shaw AT.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials..Lancet Oncol2020;21:271-82

[22] Schram AM,Jonsson P.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance..Nat Rev Clin Oncol2017;14:735-48

[23] Tuna M,Mills GB.Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors..Oncotarget2019;10:2095-111 PMCID:PMC6459343

[24] Nakanishi Y,Tsukaguchi T,Satoh Y.Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1..Mol Cancer Ther2015;14:704-12

[25] Nowell PC.Chromosome studies on normal and leukemic human leukocytes..J Natl Cancer Inst1960;25:85-109

[26] Fusco A,Santoro M,Pilotti S.A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases..Nature1987;328:170-2

[27] Gao Q,Foltz SM,Jayasinghe RG.Driver fusions and their implications in the development and treatment of human cancers..Cell Rep2018;23:227-38.e3 PMCID:PMC5916809

[28] Cilloni D.Molecular pathways: BCR-ABL..Clin Cancer Res2012;18:930-7

[29] Davare MA.Detecting and targetting oncogenic fusion proteins in the genomic era..Biol Cell2015;107:111-29 PMCID:PMC5837291

[30] Farago AF.Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer..Transl Lung Cancer Res2017;6:550-9 PMCID:PMC5653525

[31] Kwak EL,Camidge DR,Solomon B.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer..N Engl J Med2010;363:1693-703 PMCID:PMC3014291

[32] Seto T,Nishio M,Maemondo M.CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study..Lancet Oncol2013;14:590-8

[33] Shaw AT,Mehra R,Felip E.Ceritinib in ALK-rearranged non-small-cell lung cancer..N Engl J Med2014;370:1189-97 PMCID:PMC4079055

[34] Ou SH,Jalas JR,Wong V.Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation..Lung Cancer2016;96:15-8

[35] Takeuchi K,Togashi Y,Sakata S.RET, ROS1 and ALK fusions in lung cancer..Nat Med2012;18:378-81

[36] Lamarca A,McNamara MG.Molecular targeted therapies: ready for “prime time” in biliary tract cancer..J Hepatol2020;

[37] Yu YP,Nelson J,Bhargava R.Identification of recurrent fusion genes across multiple cancer types..Sci Rep2019;9:1074 PMCID:PMC6355770

[38] Frampton GM,Otto GA,Downing SR.Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing..Nat Biotechnol2013;31:1023-31 PMCID:PMC5710001

[39] Morris SW,Valentine MB,Shapiro DN.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma..Science1995;267:316-7

[40] Soda M,Enomoto M,Yamashita Y.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer..Nature2007;448:561-6

[41] Hillier K,Shamberger RC,Perez-Atayde AR.A novel ALK fusion in pediatric medullary thyroid carcinoma..Thyroid2019;29:1704-7

[42] Lipson D,Yelensky R,Parker A.Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies..Nat Med2012;18:382-4 PMCID:PMC3916180

[43] Debelenko LV,Daw N,Huang D.Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum..Mod Pathol2011;24:430-42

[44] Du XL,Lin DC,Shen XM.Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma..J Mol Med (Berl)2007;85:863-75

[45] Wiesner T,Yelensky R,Botton T.Kinase fusions are frequent in Spitz tumours and spitzoid melanomas..Nat Commun2014;5:3116 PMCID:PMC4084638

[46] Wu YM,Kalyana-Sundaram S,Ateeq B.Identification of targetable FGFR gene fusions in diverse cancers..Cancer Discov2013;3:636-47 PMCID:PMC3694764

[47] Lamballe F,Barbacid M.The trk family of oncogenes and neurotrophin receptors..Princess Takamatsu Symp1991;22:153-70

[48] Light JE,Minturn JE,Simpson AM.Clinical significance of NTRK family gene expression in neuroblastomas..Pediatr Blood Cancer2012;59:226-32 PMCID:PMC3258457

[49] Pulciani S,Lauver AV,Aaronson SA.Oncogenes in solid human tumours..Nature1982;300:539-42

[50] Lee SJ,Kim ST,Jang J.NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line..Oncotarget2015;6:39028-35 PMCID:PMC4770754

[51] Haller F,Ackermann A,Kleinheinz K.Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern..J Pathol2016;238:700-10

[52] Agaram NP,Sung YS,Chung CT.Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors..Am J Surg Pathol2016;40:1407-16 PMCID:PMC5023452

[53] Wu G,Paugh BS,Ju B.The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma..Nat Genet2014;46:444-50 PMCID:PMC4056452

[54] Shim HS,Zheng Z,Cha YJ.Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung..J Thorac Oncol2015;10:1156-62

[55] Sozzi G,Miozzo M,Mondellini P.Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas..Genes Chromosomes Cancer1992;5:212-8

[56] Wei G,Walsh C,Fagan P.Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers..Eur J Cancer2016;69:S33

[57] Nakagawara A.Trk receptor tyrosine kinases: a bridge between cancer and neural development..Cancer Lett2001;169:107-14

[58] Thiele CJ,McKee AE.On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology..Clin Cancer Res2009;15:5962-7 PMCID:PMC2756331

[59] Vaishnavi A,Doebele RC.TRKing down an old oncogene in a new era of targeted therapy..Cancer Discov2015;5:25-34 PMCID:PMC4293234

[60] Jones DT,Jager N,Kool M.Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma..Nat Genet2013;45:927-32 PMCID:PMC3951336

[61] Eguchi M,Tojo A,Suzuki K.Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)..Blood1999;93:1355-63

[62] Roberts KG,Payne-Turner D,Yang YL.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia..N Engl J Med2014;371:1005-15 PMCID:PMC4191900

[63] Forghieri F,Potenza L,Pedrazzi L.Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma..Eur J Haematol2011;86:352-5

[64] Okamura R,Kato S,Bazhenova L.Analysis of NTRK Alterations in Pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics..JCO Precis Oncol2018; PMCID:PMC6329466

[65] Weinstein IB.Oncogene addiction..Cancer Res2008;68:3077-80discussion 80

[66] Solomon JP,Hechtman JF.Identifying patients with NTRK fusion cancer..Ann Oncol2019;30:viii16-22

[67] Li G,Kim KM,Russo M.Abstract A173: potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs..Mol Cancer Ther2015;14:A173

[68] Stumpfova M.Zeroing in on ROS1 rearrangements in non-small cell lung cancer..Clin Cancer Res2012;18:4222-4

[69] Davies KD.Molecular pathways: ROS1 fusion proteins in cancer..Clin Cancer Res2013;19:4040-5 PMCID:PMC3732549

[70] Bergethon K,Ou SH,Lovly CM.ROS1 rearrangements define a unique molecular class of lung cancers..J Clin Oncol2012;30:863-70 PMCID:PMC3295572

[71] Pan Y,Li Y,Wang L.ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features..Lung Cancer2014;84:121-6

[72] Birchmeier C,Wigler M.Expression and rearrangement of the ROS1 gene in human glioblastoma cells..Proc Natl Acad Sci U S A1987;84:9270-4 PMCID:PMC299735

[73] Davare MA,Agarwal A,Iyer SR.Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma..Clin Cancer Res2018;24:6471-82 PMCID:PMC6295214

[74] Peraldo Neia C,Balsamo A,Napoli F.Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR..Genes Chromosomes Cancer2014;53:1033-40

[75] Lee J,Kang SY,Lee S.Identification of ROS1 rearrangement in gastric adenocarcinoma..Cancer2013;119:1627-35

[76] Aisner DL,Paskulin DD,Haney J.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers..Mol Cancer Res2014;12:111-8 PMCID:PMC4140177

[77] Shaw AT,Awad MM.Tyrosine kinase gene rearrangements in epithelial malignancies..Nat Rev Cancer2013;13:772-87 PMCID:PMC3902129

[78] Uguen A.ROS1 fusions in cancer: a review..Future Oncol2016;12:1911-28

[79] Neel DS,Olivas V,Hemmati G.Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins..Cancer Res2019;79:546-56 PMCID:PMC6359944

[80] Mitelman F,Mertens F.The impact of translocations and gene fusions on cancer causation..Nat Rev Cancer2007;7:233-45

[81] He Y,Hu W,Liu J.Different types of ROS1 fusion partners yield comparable efficacy to Crizotinib..Oncol Res2019;27:901-10

[82] Davare MA,Eide CA,Smith RL.Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins..Proc Natl Acad Sci U S A2013;110:19519-24 PMCID:PMC3845150

[83] Hallberg B.The role of the ALK receptor in cancer biology..Ann Oncol.2016;27 Suppl 3:iii4-15

[84] Li G,Shao FC.Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis..Eur Rev Med Pharmacol Sci2017;21:3496-503

[85] Schoffski P,Gelderblom H,Strauss SJ.Abstract CT045: Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 “CREATE”..Cancer Res2018;78:CT045

[86] Porta R,Coelho A,Araujo A.FGFR a promising druggable target in cancer: Molecular biology and new drugs..Crit Rev Oncol Hematol2017;113:256-67

[87] Helsten T,Arthur E,Carter J.The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing..Clin Cancer Res2016;22:259-67

[88] Babina IS.Advances and challenges in targeting FGFR signalling in cancer..Nat Rev Cancer2017;17:318-32

[89] Borad MJ,Roberts LR.Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma..Curr Opin Gastroenterol2015;31:264-8 PMCID:PMC4750878

[90] Arai Y,Hosoda F,Hama N.Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma..Hepatology2014;59:1427-34

[91] Jain A,Javle M.Genomic profiling of biliary tract cancers and implications for clinical practice..Curr Treat Options Oncol2016;17:58

[92] Sia D,Moeini A,Hao K.Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma..Nat Commun2015;6:6087

[93] Parker BC,Annala M.Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours..J Pathol2014;232:4-15

[94] Goyal L,Liu LY,Leshchiner I.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma..Cancer Discov2017;7:252-63 PMCID:PMC5433349

[95] Katoh M.Fibroblast growth factor receptors as treatment targets in clinical oncology..Nat Rev Clin Oncol2019;16:105-22

[96] Javle M,Shroff RT,Springfeld C.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma..J Clin Oncol2018;36:276-82 PMCID:PMC6075847

[97] Pal SK,Hoffman-Censits JH,Quinn DI.Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations..Cancer Discov2018;8:812-21 PMCID:PMC6716598

[98] Javle M,Roychowdhury S,Abou-Alfa G.LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions..Ann Oncol2018;29:

[99] Hollebecque A,Sahai V,Murphy A.Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations..Ann Oncol2018;29:viii258

[100] Park JO,Chen YY,Oh DY.Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations..J Clin Oncol2019;37:4117

[101] Meric-Bernstam F,Tran B,Kelley R.Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors..Ann Oncol2018;29:v100

[102] Li G,Roychowdhury S,Ye Y.Abstract 2206: anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors..Cancer Res2019;79:2206

[103] Nauseef JT,Lebenthal J,Tagawa ST.An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer..Expert Opin Pharmacother2020;1-8

[104] Dizman N,Hoffman-Censits JH,Petrylak DP.Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results..J Clin Oncol2019;37:4510

[105] Takahashi M.Ret transforming gene encodes a fusion protein homologous to tyrosine kinases..Mol Cell Biol1987;7:1378-85 PMCID:PMC365224

[106] Airaksinen MS.The GDNF family: signalling, biological functions and therapeutic value..Nat Rev Neurosci2002;3:383-94

[107] Mulligan LM.RET revisited: expanding the oncogenic portfolio..Nat Rev Cancer2014;14:173-86

[108] Kohno T,Tsuchihara K,Yoh K.RET fusion gene: translation to personalized lung cancer therapy..Cancer Sci2013;104:1396-400 PMCID:PMC5439108

[109] de Graaff E,Kilkenny C,Mankoo BS.Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis..Genes Dev2001;15:2433-44 PMCID:PMC312785

[110] Chi X,Shakya R,Enomoto H.Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis..Dev Cell2009;17:199-209 PMCID:PMC2762206

[111] Grieco M,Berlingieri MT,Donghi R.PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas..Cell1990;60:557-63

[112] Kondo T,Asa SL.Pathogenetic mechanisms in thyroid follicular-cell neoplasia..Nat Rev Cancer2006;6:292-306

[113] Ju YS,Shin JY,Bleazard T.A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing..Genome Res2012;22:436-45 PMCID:PMC3290779

[114] Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinoma..Nature2014;511:543-50 PMCID:PMC4231481

[115] Tsuta K,Yoshida A,Asamura H.RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis..Br J Cancer2014;110:1571-8 PMCID:PMC3960615

[116] Wang R,Pan Y,Ye T.RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer..J Clin Oncol2012;30:4352-9

[117] Kato S,Marchlik E,Carter JL.RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients..Clin Cancer Res2017;23:1988-97

[118] Chao BH,Villalona-Calero MA.RET fusion genes in non-small-cell lung cancer..J Clin Oncol2012;30:4439-41

[119] Ferrara R,Auclin E.Clinical and translational implications of RET rearrangements in non-small cell lung cancer..J Thorac Oncol2018;13:27-45

[120] Plenker D,Bragelmann J,Chauhan R.Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors..Sci Transl Med2017;9: PMCID:PMC5805089

[121] Stransky N,Schalm S,Lengauer C.The landscape of kinase fusions in cancer..Nat Commun2014;5:4846 PMCID:PMC4175590

[122] Le Rolle AF,Garrett CR,Sanford EM.Identification and characterization of RET fusions in advanced colorectal cancer..Oncotarget2015;6:28929-37 PMCID:PMC4745701

[123] Li AY,Russo A,Gittens A.Cancer Treat Rev2019;81:101911

[124] Li GG,Joseph J,Hayashi T.Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations..Clin Cancer Res2017;23:2981-90 PMCID:PMC5477238

[125] Matsubara D,Ishikawa S,Yoshimoto T.Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad..J Thorac Oncol2012;7:1872-6

[126] Subbiah V,Rahal R,Kim JL.Cancer Discov2018;8:836-49

[127] Guo R,Chang JC,Henry D.Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases..JCO Precis Oncol2019;3: PMCID:PMC6724540

[128] Drilon A,Wirth L,Gautschi O.PL02.08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers..J Thorac Oncol2019;14:S6-7

[129] Gainor JF,Curigliano G,Kim DW.Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)..J Clin Oncol2019;37:9008

[130] Lacombe D,Bogaerts J,Golfinopoulos V.The dream and reality of histology agnostic cancer clinical trials..Mol Oncol2014;8:1057-63 PMCID:PMC5528617

[131] Chu P,Hodgson M,Steenrod A.Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy..Future Oncol2020;16:61-74

[132] Davies H,Cox C,Edkins S.Mutations of the BRAF gene in human cancer..Nature2002;417:949-54

[133] Chapman PB,Robert C,Ascierto P.Improved survival with vemurafenib in melanoma with BRAF V600E mutation..N Engl J Med2011;364:2507-16 PMCID:PMC3549296

[134] Kim YS,Bae JS.Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma..World J Surg Oncol2013;11:99 PMCID:PMC3660263

[135] Kopetz S,Chan E,O’Dwyer PJ.Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer..J Clin Oncol2015;33:4032-8 PMCID:PMC4669589

[136] Ducreux M,Laurent-Puig P,Hollebecque A.Molecular targeted therapy of BRAF-mutant colorectal cancer..Ther Adv Med Oncol2019;11:1758835919856494 PMCID:PMC6582307